Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

dc.creatorOlsson, SE
dc.creatorVilla, LL
dc.creatorCosta, RLR
dc.creatorPetta, CA
dc.creatorAndrade, RP
dc.creatorMalm, C
dc.creatorIversen, OE
dc.creatorHoye, J
dc.creatorSteinwall, M
dc.creatorRiis-Johannessen, G
dc.creatorAndersson-Ellstrom, A
dc.creatorElfgren, K
dc.creatorvon Krogh, G
dc.creatorLehtinen, M
dc.creatorPaavonen, J
dc.creatorTamms, GM
dc.creatorGiacoletti, K
dc.creatorLupinacci, L
dc.creatorEsser, MT
dc.creatorVuocolo, SC
dc.creatorSaah, AJ
dc.creatorBarr, E
dc.date2007
dc.date44348
dc.date2014-11-19T09:02:04Z
dc.date2015-11-26T18:01:42Z
dc.date2014-11-19T09:02:04Z
dc.date2015-11-26T18:01:42Z
dc.date.accessioned2018-03-29T00:43:18Z
dc.date.available2018-03-29T00:43:18Z
dc.identifierVaccine. Elsevier Sci Ltd, v. 25, n. 26, n. 4931, n. 4939, 2007.
dc.identifier0264-410X
dc.identifierWOS:000247547400009
dc.identifier10.1016/j.vaccine.2007.03.049
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/60102
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/60102
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/60102
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1292048
dc.descriptionBackground: The duration of protection afforded by vaccines represents a critical test of their utility as public health interventions. Some vaccines induce long-term immunity, while others require booster doses. Vaccines that induce long-term protection are usually characterized by the generation of immune memory. Recent trials of a quadrivalent (types 6, 11, 16, 18) human papillomavirus (HPV) vaccine have demonstrated high efficacy through 5 years of follow-up. We evaluated the extent to which the vaccine is able to generate HPV type-specific immune memory. Methods: A total of 552, 16-23-year-old women were enrolled in a double-blind, placebo-controlled study. At enrollment, subjects were randomized in a 1:1 ratio to receive three-dose regimens of quadrivalent HPV vaccine or placebo with 3 years' follow-up. A subset of 241 subjects (n = 114 in the quadrivalent HPV vaccine group and n = 127 in the placebo group) underwent 2 further years of follow-up. All extension subjects received quadrivalent HPV vaccine at month 60 to examine the extent of immune memory in response to the primary vaccination series.
dc.description25
dc.description26
dc.description4931
dc.description4939
dc.languageen
dc.publisherElsevier Sci Ltd
dc.publisherOxford
dc.publisherInglaterra
dc.relationVaccine
dc.relationVaccine
dc.rightsfechado
dc.rightshttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.sourceWeb of Science
dc.subjecthuman papillomavirus
dc.subjectprophylactic vaccine
dc.subjectvirus-like particles
dc.subjectcervical intraepithelial neoplasia (CIN)
dc.subjectgenital warts
dc.subjectcervical cancer
dc.subjectclinical trial
dc.subjectB Surface-antigen
dc.subjectHepatitis-b
dc.subjectNeutralizing Epitopes
dc.subjectGenital Warts
dc.subjectImmunogenicity
dc.subjectAntibodies
dc.subjectCancer
dc.subjectResponses
dc.subjectTrial
dc.subjectHuman-papillomavirus-16
dc.titleInduction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución